HMDS, Department of Haematology, St. James's Institute of Oncology, Leeds, United Kingdom.
Hematology Am Soc Hematol Educ Program. 2009:430-9. doi: 10.1182/asheducation-2009.1.430.
The incidence and presenting features of chronic lymphocytic leukemia (CLL) have changed significantly over the last century. Routine diagnostic techniques can now detect very low levels of CLL phenotype cells. Monoclonal B-cell lymphocytosis (MBL) is a relatively recent diagnostic category encapsulating individuals with an abnormal B-cell population but not meeting the diagnostic criteria for a B-cell malignancy. This review focuses on CLL-type MBL, which represents the majority of MBL cases identified in diagnostic laboratories. CLL-type MBL has a phenotype identical to CLL and shares the same chromosomal abnormalities even at the lowest levels detectable. Recent evidence suggests that the immunoglobulin gene usage plays a key role in whether the abnormal cells will develop in significant numbers. In most cases, CLL-type MBL is a stable condition with only 1% per year among those presenting for clinical attention developing progressive disease requiring treatment, although suppressed immune function may have a more significant impact on outcome.
在过去的一个世纪中,慢性淋巴细胞白血病 (CLL) 的发病率和临床表现发生了显著变化。现在常规的诊断技术可以检测到非常低水平的 CLL 表型细胞。单克隆 B 细胞淋巴增生症 (MBL) 是一个相对较新的诊断类别,它包含了具有异常 B 细胞群但不符合 B 细胞恶性肿瘤诊断标准的个体。本篇综述主要关注 CLL 型 MBL,它代表了在诊断实验室中发现的大多数 MBL 病例。CLL 型 MBL 的表型与 CLL 相同,甚至在可检测到的最低水平也具有相同的染色体异常。最近的证据表明,免疫球蛋白基因的使用在异常细胞是否会大量出现中起着关键作用。在大多数情况下,CLL 型 MBL 是一种稳定的状态,在因临床关注而就诊的患者中,每年只有 1%会发展为需要治疗的进行性疾病,尽管免疫功能受抑制可能对预后有更重大的影响。